Acquisition adds seven  commercial products including VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), and MIPLYFFA® (arimoclomol), and more than 100 development and commercial-stage assets, creating long-term opportunities to drive growth Ligand to provide updated 5-year outlook during Investor Day on December 8, 2026 JUPITER, Fla., July 14, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced it has completed its acquisition of XOMA Royalty Corporation (“XOMA Royalty”), a biotechnology royalty aggregator, for $39.00 per share of common stock in cash, for a total equity value of approximately $739 million.

globenewswire.com - 2026-07-14 09:00:00

EMERYVILLE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation today announced that Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has completed its previously announced acquisition of XOMA Royalty.

globenewswire.com - 2026-07-14 09:00:00

The S&P 500 is up 10.3% YTD, and Wall Street is convinced the markets have more room to run, particularly for this group of stocks we have uncovered. JPMorgan just tagged CECO Environmental (NASDAQ: CECO) with a $130 price target, implying roughly 65% upside from where the stock closed Friday. Bigger and more interesting calls landed on... 5 Stock Setups Where Wall Street Sees the Most Upside Right Now

247wallst.com - 2026-07-12 22:44:47

Ligand Pharmaceuticals has delivered exceptional long-term returns, rising from ~$86 to nearly $300 over six years. Recent developments include a significant Xoma acquisition and portfolio advancements. I closely review LGND's Q1 2026 earnings, highlighting operational and financial performance and strategic moves.

seekingalpha.com - 2026-06-30 21:40:10

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 25, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today that it completed its previously announced offering (the “offering”) of 0.00% convertible senior notes due 2031 (the “notes”).

globenewswire.com - 2026-06-25 16:01:00

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $625.0 million aggregate principal amount of 0.0% convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

globenewswire.com - 2026-06-23 04:00:00

Opportunistic capital raise with proceeds used to enhance financial flexibility  A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $550.0 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors.

globenewswire.com - 2026-06-22 07:00:00

Kozarich sold 2,501 common shares. This transaction represented 5.65% of direct holdings.

fool.com - 2026-06-14 07:00:01

JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 10:30 a.m.

globenewswire.com - 2026-06-10 07:00:00

5,000 shares were sold for a total transaction value of ~$1.14 million on June 1, 2026, at a weighted average price around $227.06 per share. This sale represented 10.78% of Andrew Reardon's direct Common Stock holdings, reducing direct ownership to 41,382 shares post-transaction.

fool.com - 2026-06-07 08:28:38

JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Stifel 2026 Boston Cross Sector 1x1 Conference.

globenewswire.com - 2026-05-27 16:01:00

Ligand Pharmaceuticals Incorporated will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. XOMA shareholders will receive a Contingent Value Right, or CVR, for 75% of net proceeds from certain pending litigation. The transaction is expected to close in Q3 2026 and be immediately accretive to LGND earnings per share.

seekingalpha.com - 2026-05-25 08:00:00

Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.

marketbeat.com - 2026-05-08 16:13:30

First quarter performance driven by strong year-over-year royalty revenue growth of  56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

globenewswire.com - 2026-05-07 07:00:00

NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a $15 million payment from Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) pursuant to the previously disclosed Revenue Participation Right Purchase and Sale Agreement (the “Royalty Purchase Agreement”). The payment completes a scheduled tranche under the agreement and reflects Ligand's continued strategic capital support of Orchestra BioMed's late-stage cardiovascular programs, AVIM Therapy and Virtue SAB, which are both being evaluated in ongoing randomized, controlled pivotal trials.

globenewswire.com - 2026-05-06 08:01:00

JUPITER, Fla., May 05, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: H.C.

globenewswire.com - 2026-05-05 16:01:00

BALA CYNWYD, Pa. , May 05, 2026 (GLOBE NEWSWIRE) -- Brodsky and Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith. com) or Marc Ackerman (mackerman@brodskysmith. com) at 855-576-4847.

globenewswire.com - 2026-05-05 14:33:06

Ligand Pharmaceuticals (NASDAQ: LGND) detailed plans to acquire XOMA Royalty Corporation in an investor call, outlining what executives described as a "highly complementary" transaction intended to expand Ligand's royalty portfolio and accelerate growth. Under the definitive agreement, Ligand will pay $39 per share in cash to XOMA Royalty shareholders, with a contingent value right (CVR) tied

defenseworld.net - 2026-04-29 15:13:29

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of XOMA Royalty Corporation (NasdaqGM: XOMA) to Ligand Pharmaceuticals Incorporated (NasdaqGM: LGND). Under the terms of the proposed transaction, shareholders of XOMA will receive $39.00 in cash for each share of XOMA that they own. KSF is seeking to determine whether this consideration and the process.

businesswire.com - 2026-04-28 12:45:00

NEW YORK, April 27, 2026 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by XOMA Royalty Corporation (NASDAQ: XOMA) and its board of directors concerning the proposed acquisition of the company by Ligand Pharmaceuticals Incorporated (NASDAQ: LGND). Stockholders will receive $39.00 and one contingent value right for each share of XOMA Royalty stock that they hold.

prnewswire.com - 2026-04-27 15:06:00

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) on Monday said it is expanding its royalty portfolio through the acquisition of XOMA Royalty Corporation (NASDAQ:XOMA).

benzinga.com - 2026-04-27 13:18:03

Ligand Pharmaceuticals Incorporated (LGND) M&A Call Transcript

seekingalpha.com - 2026-04-27 10:01:32

Ligand Pharmaceuticals will buy fellow biotechnology royalty aggregator XOMA Royalty for about $739 million in cash, the ​companies said on Monday.

reuters.com - 2026-04-27 08:12:19

Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.50 1 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 2027 2 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla.

globenewswire.com - 2026-04-27 07:00:00

Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.50 1 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 2027 2 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla.

globenewswire.com - 2026-04-27 07:00:00

Ligand and Xoma are known as royalty aggregators that invest in drugs during development and collect royalties from their sales if the drugs succeed.

wsj.com - 2026-04-27 06:00:00

B. Metzler seel. Sohn and Co. AG purchased a new position in shares of Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 6,879 shares of the biotechnology company's stock, valued at approximately $1,301,000. Other

defenseworld.net - 2026-04-27 03:48:42

PARIS, France – 22 April 2026: Coave Therapeutics (“Coave”), a company redefining targeted gene therapy with a best-in-class pipeline powered by ligand-conjugated vectors, today announces it will deliver two poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting being held 3-7 May 2026 in Denver, Colorado, as well as a company presentation at Eyecelerator @ ARVO on 1 May 2026.

globenewswire.com - 2026-04-22 07:00:00

JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026.

globenewswire.com - 2026-04-22 07:00:00